Sign inJoin waitlistJoin the waitlist

Christine Heske

Investigator · Clinical Center at the National Institutes of Health

Credentials: · · ·

History

Clinical Center at the National Institutes of Health
Present

Research

Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma
Cancer Research · 2019 · Last of 28 authors · Corresponding · 116 citations
An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials
Review · Pediatric Blood & Cancer · 2022 · 109 citations
Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy
Review · Frontiers in Oncology · 2019 · Sole author · 88 citations

LH
Lee Helman
8 papers
Rajkumar Venkatramani
8 papers
LM
Leo Mascarenhas
7 papers
Javed Khan
6 papers
Marielle Yohe
6 papers
Corinne Linardic
5 papers · 3 as a resident
FC
Filemon Cruz
5 papers
Anusua Dasgupta
4 papers
Douglas Hawkins
4 papers
CK
Charles Keller
3 papers
DR
Damon Reed
3 papers
Eleanor Chen
3 papers

Grants

Development and Translation of Novel Therapies for Pediatric Sarcoma
National Cancer Institute · ZIA
Contact PI · $9.3M · Division of Basic Sciences - Nci
Development of Biologic Based Therapies for Rhabdomyosarcoma
National Cancer Institute · ZIA
Contact PI · $1.1M · Division of Basic Sciences - Nci

Clinical trials

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Principal investigator · Recruiting · Phase 3
Children's Oncology Group
2026–2031
Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
Principal investigator · Suspended · Phase 1, Phase 2
National Cancer Institute (NCI)
2024–2027
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
Principal investigator · Terminated · Phase 1, Phase 2
National Cancer Institute (NCI)
2017–2021